Last updated: October 27, 2026
Lartruvo, Eli Lilly’s olaratumab, moved from accelerated approval in 2016 to commercial withdrawal after its required confirmatory trial failed to show an overall-survival benefit. Global sales rose rapidly before the failure, reaching approximately $300 million in 2018, then declined as new treatment initiation stopped and the product was withdrawn from major markets. Lartruvo no longer has a viable commercial market in the United States or European Union, and its remaining value is limited to historical revenue analysis, regulatory precedent, and residual intellectual-property rights.
What was Lartruvo, and how did the drug work?
Lartruvo was a human monoclonal antibody targeting platelet-derived growth factor receptor alpha, or PDGFR-alpha. Eli Lilly developed it for advanced soft-tissue sarcoma, a group of rare mesenchymal cancers with limited treatment options.
The FDA approved Lartruvo on October 19, 2016, under the accelerated-approval pathway. The approved regimen combined olaratumab with doxorubicin for adults with unresectable or metastatic soft-tissue sarcoma who had not received prior anthracycline treatment or were otherwise eligible for doxorubicin-based therapy.
The approval was based primarily on a randomized phase 2 study that reported:
| Measure |
Lartruvo plus doxorubicin |
Doxorubicin alone |
| Median overall survival |
26.5 months |
14.7 months |
| Median progression-free survival |
8.2 months |
4.4 months |
| Objective response rate |
18.2% |
11.9% |
The survival difference in the small phase 2 study drove the accelerated approval, but the trial was not designed to provide definitive confirmation. The required phase 3 ANNOUNCE trial later failed to confirm the benefit.
When did Lartruvo lose exclusivity and regulatory support?
Lartruvo lost practical commercial exclusivity in 2019, when the FDA and Lilly stopped new-patient use after the ANNOUNCE trial failed. The FDA announced on January 18, 2019, that health-care professionals should not initiate treatment in new patients outside clinical trials. Existing patients could complete treatment after consultation with their physicians.
Lilly announced on April 25, 2019, that it would voluntarily withdraw Lartruvo from the U.S. market. The European Commission withdrew the product’s marketing authorization in June 2019 following the European Medicines Agency’s review.
Lartruvo regulatory timeline
| Date |
Event |
| October 19, 2016 |
FDA grants accelerated approval for Lartruvo plus doxorubicin |
| 2017 |
U.S. and international commercial launch expands |
| January 18, 2019 |
FDA advises against initiating Lartruvo in new patients |
| January 2019 |
ANNOUNCE topline results fail to confirm overall-survival benefit |
| April 25, 2019 |
Lilly announces voluntary U.S. withdrawal |
| June 2019 |
European authorization withdrawn |
| 2019 onward |
Commercial activity becomes limited to remaining treatment courses and inventory |
Lartruvo’s FDA approval was not maintained as an active commercial indication. The product’s failure was therefore regulatory and clinical, not simply a loss of ordinary patent protection.
What did the ANNOUNCE trial show?
The ANNOUNCE phase 3 trial enrolled 509 patients with advanced or metastatic soft-tissue sarcoma. It tested olaratumab plus doxorubicin against doxorubicin plus placebo.
The trial found no statistically significant overall-survival benefit in the full study population or in the leiomyosarcoma subgroup. The median overall survival in the overall population was approximately 20.4 months for the olaratumab arm and 19.7 months for the control arm.
The result eliminated the clinical basis for continued use of Lartruvo with doxorubicin. It also exposed the risk of relying on a small phase 2 survival signal in a rare, heterogeneous tumor population.
The commercial impact was immediate because Lartruvo’s revenue depended on use in combination with first-line doxorubicin. Once physicians stopped starting new patients, recurring sales were structurally impaired.
How did Lartruvo revenue develop?
Lartruvo generated rapid sales growth after launch, but its revenue base remained concentrated in a narrow indication and dependent on continued physician confidence in the survival benefit.
Public Lilly reporting indicates the following approximate trajectory:
| Fiscal year |
Approximate Lartruvo revenue |
Commercial context |
| 2016 |
Minimal |
U.S. launch in fourth quarter |
| 2017 |
Approximately $100 million |
Initial adoption in soft-tissue sarcoma |
| 2018 |
Approximately $300 million |
Peak commercial year before confirmatory failure |
| 2019 |
Material decline |
New-patient use halted and withdrawal initiated |
| 2020 onward |
No meaningful ongoing commercial franchise |
Product withdrawn from principal markets |
Lilly reported that Lartruvo revenue increased substantially in 2018 before the ANNOUNCE result became available. The product’s 2018 performance reflected accelerated-approval commercialization, not a mature long-term revenue base. The market treated the phase 3 failure as a near-total impairment of future sales potential.
Financial trajectory by commercial phase
Launch and accelerated-approval expansion
The 2016 approval gave Lilly a first-mover position in a rare cancer setting. Lartruvo benefited from several commercial factors:
- A limited treatment landscape for advanced soft-tissue sarcoma.
- A positive overall-survival signal in the phase 2 study.
- Combination use with an established chemotherapy backbone.
- Physician demand for alternatives in a high-unmet-need disease.
- Orphan-drug positioning and a relatively concentrated specialist prescriber base.
The launch had favorable initial economics because the product was an add-on biologic to doxorubicin rather than a replacement for an established targeted therapy.
Peak sales
Lartruvo reached its highest reported sales in 2018. The revenue level was commercially meaningful for a product serving a rare tumor type, but it was small relative to Lilly’s largest franchises. The peak was also fragile because treatment depended on a single confirmatory trial.
Collapse after the phase 3 failure
The 2019 revenue decline was caused by a regulatory and clinical event rather than normal competition. There was no need for a generic or biosimilar to enter the market. Physicians stopped initiating new treatment because the required trial failed to verify benefit, and Lilly withdrew the product.
The financial profile therefore shifted from growth-stage oncology asset to discontinued product. Manufacturing, commercial, medical-affairs, and distribution spending would also have been reduced after withdrawal, but the lost revenue opportunity was much larger than any short-term operating-cost savings.
What patents protected Lartruvo?
Lartruvo was protected primarily by biologic patent rights covering anti-PDGFR-alpha antibodies and related therapeutic uses. Because olaratumab was a monoclonal antibody, its regulatory exclusivity and patent framework differed from that of a conventional small-molecule drug.
Public patent databases identify U.S. patent families directed to anti-PDGFR-alpha antibodies, including patents associated with the following types of claims:
| Patent category |
Protection target |
Commercial relevance |
| Composition of matter |
Anti-PDGFR-alpha antibodies and binding sequences |
Core biologic protection |
| Functional antibody claims |
Antibodies that bind specified PDGFR-alpha epitopes or inhibit receptor activity |
May constrain biosimilar or antibody-engineering alternatives |
| Therapeutic-use claims |
Treatment of tumors or sarcoma using anti-PDGFR-alpha antibodies |
Potential method-of-use protection |
| Combination-use claims |
Use with doxorubicin or other anticancer agents |
Narrower protection tied to the failed regimen |
| Manufacturing and formulation claims |
Production, stability, or pharmaceutical compositions |
Potential process or product support |
U.S. Patent No. 8,871,208 is publicly associated with anti-PDGFR-alpha antibody technology and has been cited in connection with olaratumab-related patent coverage. Patent term calculations can vary based on terminal disclaimers, patent-term adjustment, priority claims, and regulatory extensions. A patent’s nominal expiration date also does not determine whether a product has an active commercial market.
Did Lartruvo have Orange Book listings?
No conventional Orange Book listing should be expected for Lartruvo because the Orange Book primarily covers approved small-molecule drugs and certain drug products. Lartruvo is a biologic. Its relevant FDA regulatory records are associated with the Biologics License Application framework and the Purple Book rather than the ordinary Orange Book patent-certification system.
That distinction matters for Paragraph IV analysis. A biosimilar applicant does not ordinarily challenge Lartruvo patents through the same Abbreviated New Drug Application certification process used for small-molecule generics.
Were there Paragraph IV challenges or biosimilar competitors?
There was no commercially material Paragraph IV generic challenge to Lartruvo. The product was a monoclonal antibody, so a follow-on competitor would generally pursue the biosimilar pathway under the Biologics Price Competition and Innovation Act rather than file a conventional ANDA.
No approved biosimilar competitor became a meaningful market participant before Lartruvo was withdrawn. The absence of biosimilar entry was not the reason for the product’s collapse. The decisive event was the failure of the ANNOUNCE trial.
Lartruvo was also a poor biosimilar target after withdrawal because:
- The reference product no longer had a commercially viable indication.
- Demand for the therapy collapsed after the negative trial.
- Physicians had little incentive to switch to a follow-on product for a treatment that no longer had demonstrated benefit.
- A biosimilar developer would face development costs without a durable addressable market.
- The combination regimen depended on a failed clinical premise rather than manufacturing substitution alone.
What was the competitive landscape for Lartruvo?
Lartruvo competed in a fragmented soft-tissue-sarcoma market rather than against a single direct substitute.
| Therapy or class |
Role in the market |
Effect on Lartruvo |
| Doxorubicin |
Established first-line chemotherapy backbone |
Partner drug in Lartruvo regimen and direct control arm |
| Ifosfamide |
Chemotherapy option in selected patients |
Alternative treatment strategy |
| Gemcitabine-based regimens |
Later-line or histology-specific use |
Competitive pressure after progression |
| Pazopanib |
Approved targeted therapy for certain advanced soft-tissue sarcomas |
Non-overlapping but relevant alternative |
| Trabectedin |
Treatment option for selected liposarcoma and leiomyosarcoma patients |
Later-line competition |
| Eribulin |
Option in specific sarcoma settings |
Histology-dependent alternative |
| Surgery and radiation |
Local-control strategies |
Relevant in earlier or selected disease |
| Clinical trials |
Experimental targeted and immuno-oncology approaches |
Important substitute in specialist centers |
Lartruvo’s value proposition was strongest when its apparent survival benefit differentiated it from chemotherapy alone. Once that benefit disappeared, the product lost its primary competitive advantage.
What formulation and manufacturing protections applied?
Lartruvo was supplied as an intravenous biologic infusion. Potential intellectual-property coverage could include antibody sequence, receptor-binding characteristics, pharmaceutical composition, stability, and manufacturing processes. The commercial importance of those rights was limited after withdrawal.
For a monoclonal antibody, manufacturing barriers can be more important than patent expiry alone. A follow-on developer must establish:
- High similarity to the reference antibody.
- Consistent glycosylation and other critical quality attributes.
- Comparable potency and receptor binding.
- Acceptable impurity and aggregation profiles.
- Scalable mammalian-cell production.
- Validated analytical and stability methods.
Those barriers could have delayed biosimilar entry, but they did not preserve Lartruvo’s market. The negative clinical result made manufacturing exclusivity economically irrelevant.
Did Lilly license or partner Lartruvo?
Lilly was the principal commercial sponsor and holder of the Lartruvo franchise. Lartruvo was not associated with a major external co-commercialization transaction comparable to the licensing structures used for many oncology biologics.
The asset originated from antibody research related to PDGFR-alpha biology and was developed through Lilly’s oncology organization. Publicly reported Lartruvo economics were therefore primarily tied to Lilly’s own development, manufacturing, sales, and regulatory activities rather than a large royalty-sharing partnership.
What litigation and settlement agreements affected Lartruvo?
No major patent litigation or generic settlement drove Lartruvo’s market outcome. The principal event was the FDA and Lilly response to the failed ANNOUNCE trial.
The absence of Paragraph IV litigation, biosimilar litigation, or a generic settlement is commercially significant. It shows that Lartruvo’s loss of value came from clinical validation failure rather than a negotiated early-entry arrangement.
How does Lartruvo compare with durable oncology biologics?
Lartruvo’s commercial trajectory differs from products that combine a broad indication, multiple lines of therapy, biomarker selection, or several approved combinations.
| Factor |
Lartruvo |
Durable oncology biologic |
| Indication breadth |
Narrow |
Often broad or expandable |
| Confirmatory evidence |
Failed |
Positive or consistently supportive |
| Treatment setting |
Specialized sarcoma population |
Larger or multiple populations |
| Revenue diversification |
Low |
Higher |
| Combination options |
Primarily doxorubicin |
Multiple validated regimens |
| Biosimilar threat |
Low after withdrawal |
Material after market maturity |
| Revenue durability |
Short |
Potentially multi-cycle |
| Regulatory status |
Withdrawn from key markets |
Active approval base |
Lartruvo’s high concentration in one rare indication magnified the impact of the clinical failure. It lacked a second indication, biomarker-defined responder population, or alternative treatment combination that could have supported a salvage strategy.
What generic launch risks existed for Lartruvo?
Traditional generic launch risk was low because Lartruvo was a biologic and had no meaningful small-molecule generic pathway. The relevant risks were different:
- A biosimilar could theoretically have entered after regulatory and patent barriers were addressed.
- An antibody with a different molecular design could have competed through a separate biologic program.
- Physicians could substitute established chemotherapy or other sarcoma therapies without waiting for patent expiry.
- Withdrawal eliminated the economic incentive for follow-on development.
The most important launch scenario was therefore not an early generic launch. It was the immediate substitution of alternative cancer treatments after the confirmatory trial failed.
What is the remaining revenue exposure for Lilly?
Lartruvo’s remaining direct revenue exposure is negligible after withdrawal from the U.S. and European markets. Any later revenue would have been limited to residual inventory, treatment continuation by existing patients, or minor sales in jurisdictions with delayed withdrawal procedures.
The larger financial consequences were indirect:
- Lost future revenue from a product that had reached approximately $300 million in annual sales.
- Reduced return on phase 3 development and commercialization spending.
- Potential impairment of intangible assets and inventory.
- Reduced confidence in the PDGFR-alpha therapeutic strategy.
- Opportunity cost from commercial and manufacturing resources allocated to the asset.
- Lower probability of expanding the product into additional sarcoma or solid-tumor indications.
Lartruvo was not large enough to materially alter Lilly’s overall corporate trajectory, but the failure was material to its oncology portfolio and to the economics of accelerated approval in rare cancers.
How strong was the Lartruvo patent estate?
The patent estate was technically meaningful but commercially weak after 2019. Core antibody claims could have remained relevant for years beyond withdrawal, while formulation and manufacturing claims might have complicated follow-on development. Those rights did not protect the product against the more important risk: loss of clinical utility.
Patent strength should be assessed across four dimensions:
| Dimension |
Assessment |
| Molecular protection |
Potentially meaningful for anti-PDGFR-alpha antibody sequences and binding properties |
| Regulatory exclusivity |
Strong during the original biologic exclusivity period, but commercially irrelevant after withdrawal |
| Formulation and manufacturing |
Potential secondary barriers, dependent on claim scope and validity |
| Market protection |
Failed because clinical evidence no longer supported use |
Lartruvo demonstrates that a strong biologic patent position cannot compensate for a failed confirmatory trial when approval depends on accelerated-approval validation.
Key Takeaways
- Lartruvo was Eli Lilly’s olaratumab monoclonal antibody for advanced soft-tissue sarcoma.
- FDA accelerated approval came in October 2016.
- Sales rose to approximately $300 million in 2018 before the confirmatory trial failed.
- The ANNOUNCE phase 3 trial did not confirm an overall-survival benefit.
- The FDA advised against new-patient initiation in January 2019.
- Lilly withdrew Lartruvo from the U.S. market in April 2019, and European authorization was withdrawn later that year.
- No meaningful generic, biosimilar, Paragraph IV, or patent-settlement event caused the commercial decline.
- The product’s patent estate could have remained active after withdrawal, but its market value collapsed because clinical utility was not confirmed.
- Lartruvo’s primary business lesson is the financial fragility of narrow oncology assets commercialized under accelerated approval.
FAQs About Lartruvo Market and Financial Performance
What was Lartruvo’s peak annual revenue?
Lartruvo generated approximately $300 million in revenue in 2018, its peak commercial year before the ANNOUNCE trial failure and subsequent withdrawal.
Is Lartruvo still approved by the FDA?
Lartruvo is no longer commercially available for routine new-patient treatment in the United States. Lilly voluntarily withdrew the product after the required confirmatory trial failed to verify clinical benefit.
Could a biosimilar company launch olaratumab?
A biosimilar pathway was theoretically possible, but no commercially relevant biosimilar emerged. Withdrawal and the failed clinical evidence eliminated the market incentive to develop a follow-on product.
Did Lartruvo lose market share to a competing drug?
The product did not lose share through ordinary competitive erosion. Use declined after physicians and regulators responded to the failed ANNOUNCE trial. Patients shifted to chemotherapy, approved sarcoma therapies, and clinical trials.
What happened to Lartruvo’s patent rights after withdrawal?
Withdrawal did not automatically terminate issued patent rights. Patent protection could continue until the applicable expiration dates, subject to validity, enforceability, terminal disclaimers, and other term adjustments. The rights had limited commercial value because the product no longer had a viable market.
References
- Eli Lilly and Company. (2018). 2018 annual report.
- Eli Lilly and Company. (2019). 2019 annual report.
- European Medicines Agency. (2019). Lartruvo: Withdrawal of the marketing authorisation.
- U.S. Food and Drug Administration. (2016). FDA grants accelerated approval to olaratumab for soft tissue sarcoma.
- U.S. Food and Drug Administration. (2019, January 18). FDA statement on new patients not starting treatment with Lartruvo outside of clinical trials.
- Tap, W. D., Jones, R. L., Van Tine, B. A., Chmielowski, B., Elias, A. D., Adkins, D., et al. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of advanced or metastatic soft-tissue sarcoma: A randomised double-blind phase 2 trial. The Lancet, 388(10043), 488-497.
- Tap, W. D., Wagner, A. J., Papai, Z., Ganjoo, K. N., Elias, A. D., Chawla, S. P., et al. (2022). ANNOUNCE: A phase III randomized, placebo-controlled trial of olaratumab for metastatic soft-tissue sarcoma. Journal of Clinical Oncology, 40(7), 729-738.
- U.S. Patent No. 8,871,208. (2014). Anti-PDGFR-alpha antibodies and methods of use thereof. United States Patent and Trademark Office.